Early Phase Development
Nathalie Chauret joined BELLUS Health in 2017 and is currently Vice President, Early Phase Development. She oversees all toxicity and clinical pharmacology activities.
Ms. Chauret has over 25- years of experience in drug discovery and drug development in the biopharmaceutical industry. Prior to joining BELLUS Health, N. Chauret led DMPK and Phase 1 clinical activities with increasing responsibilities at Merck Frosst, Virochem Pharma and Vertex Pharmaceuticals. Throughout her career, she has been involved in the discovery and development of several marketed drugs in different therapeutic areas (asthma, pain and osteoporosis).
Ms. Chauret holds a Master’s degree in Chemistry from the Université of Montreal and has published over 50 research papers, abstracts and patents.
At BELLUS Health, we work together to achieve a common goal and I am honored to be a part of a solid team of experts whose dedication to quality consistently comes through.